Intraocular pressure changes following intravitreal anti-VEGF injections in AMD patients

age-related macular degeneration (AMD) as well as other eye disorders linked to choroidal neovascularisation (CNV). The present study was assessed intraocular pressure changes following intravitreal anti-VEGF injections in AMD patients. Materials & Methods: 45 wet age-related macular degeneration (AMD) patients of both genderswere divided into 3 groups of 15 each. Group I patients received bevacizumab (1.25 mg/0.05 ml), group II patients received ranibizumab (0.5 mg/ 0.05 ml)and group III patients received both bevacizumab (1.25 mg/0.05 ml), and ranibizumab (0.5 mg/ 0.05 ml). Parameters such as prevalence of intraocular pressure elevations and mean interval between injections (days) were recorded. Results: There were 15 patients and 30 eyes in all groups. The mean age was 68.4 years, 70.2 years and 74.2 years and pre-existing glaucoma was seen in 4, 3 and 1 patient in group I, II and III respectively. The difference was significant (P< 0.05). In pre-existing glaucoma, IOP elevations was seen in 3, in group I in 2, in group II in 2 and in group III in 0 patients. The mean interval between injections was 65.2 days, 87.5 days, 54.2 days and 50.4 days respectively. The difference was significant (P< 0.05). Conclusion: The occurrence of sustained elevated IOP in patients receiving intravitreal anti-VEGF injections is considerable. Moreover, these data indicate that patients with pre-existing glaucoma who are treated with either bevacizumab or ranibizumab may have an increased risk of further IOP elevation.